IL6 and anemia: Taken together all the results, alternatively to the hepcidin agonists or antagonists as therapeutic tools (20), bLf oral administration can be considered as a first promising compound in treating anemia through the decrease of both IL-6 and hepcidin thus restoring Fpn-mediated iron export from cells to blood in an hepcidin dependent or independent way.